WBR0629: Difference between revisions

Jump to navigation Jump to search
No edit summary
m (refreshing WBR questions)
 
(10 intermediate revisions by one other user not shown)
Line 1: Line 1:
{{WBRQuestion
{{WBRQuestion
|QuestionAuthor={{Rim}}
|QuestionAuthor= {{Rim}} (Reviewed by  {{Rim}})
|ExamType=USMLE Step 1
|ExamType=USMLE Step 1
|MainCategory=Biostatistics/ Epidemiology
|MainCategory=Biostatistics/Epidemiology
|SubCategory=Cardiology
|SubCategory=Cardiology
|MainCategory=Biostatistics/ Epidemiology
|MainCategory=Biostatistics/Epidemiology
|SubCategory=Cardiology
|SubCategory=Cardiology
|MainCategory=Biostatistics/ Epidemiology
|MainCategory=Biostatistics/Epidemiology
|SubCategory=Cardiology
|SubCategory=Cardiology
|MainCategory=Biostatistics/ Epidemiology
|MainCategory=Biostatistics/Epidemiology
|MainCategory=Biostatistics/ Epidemiology
|MainCategory=Biostatistics/Epidemiology
|MainCategory=Biostatistics/Epidemiology
|MainCategory=Biostatistics/Epidemiology
|SubCategory=Cardiology
|SubCategory=Cardiology
|MainCategory=Biostatistics/ Epidemiology
|MainCategory=Biostatistics/Epidemiology
|SubCategory=Cardiology
|SubCategory=Cardiology
|MainCategory=Biostatistics/ Epidemiology
|MainCategory=Biostatistics/Epidemiology
|SubCategory=Cardiology
|SubCategory=Cardiology
|MainCategory=Biostatistics/ Epidemiology
|MainCategory=Biostatistics/Epidemiology
|SubCategory=Cardiology
|SubCategory=Cardiology
|MainCategory=Biostatistics/ Epidemiology
|MainCategory=Biostatistics/Epidemiology
|MainCategory=Biostatistics/ Epidemiology
|MainCategory=Biostatistics/Epidemiology
|SubCategory=Cardiology
|SubCategory=Cardiology
|Prompt=A study addresses the use of a novel cholesterol lowering drug among patients with one or more previous episodes of acute coronary syndrome (ACS) for the prevention of the recurrence of ACS. Five year follow up reveals recurrence of ACS among 200 out of 2000 subjects who were administered the drug under investigation versus 540 out of 2400 subjects who were administered placebo. What is the number to treat for the novel drug during 5 years?
|Prompt=A study addresses the secondary prevention of acute coronary syndrome (ACS) using a novel cholesterol-lowering agent. After 5 years, follow-up of 4400 ACS patients reveals recurrence of at least 1 ACS event among 200 out of 2000 subjects who were administered the novel agent vs. 540 out of 2400 subjects who were administered standard therapy. Through 5 years, how many patients should be administered the novel agent to prevent at least 1 ACS event?
|Explanation=The [[number needed to treat]] (NNT) is an [[epidemiology|epidemiological]] measure that indicates how many patients would require treatment with a form of [[medication]] to reduce the expected number of cases of a defined endpoint by one. It is defined as the inverse of the [[absolute risk reduction]]. In this question the drug reduces the risk of recurrence of [[ACS]] from 22.5% to 10%. Therefore the absolute risk reduction is 12.5%. The NNT for a 5-year treatment with the drug is the inverse of the absolute risk reduction, and it is 8%.
|Explanation=The [[number needed to treat]] (NNT) is an [[epidemiology|epidemiological]] measure that indicates how many patients would require treatment with a form of [[medication]] to reduce the expected number of cases of a defined endpoint by one. It is defined as the inverse of the [[absolute risk reduction]]. In this vignette, the drug reduces the risk of recurrence of [[ACS]] from 22.5% to 10%. Therefore the absolute risk reduction is 12.5%. The NNT for a 5-year treatment with the novel cholesterol-lowering agent is the inverse of the absolute risk reduction (ARR), where ARR is the absolute difference in the event rate between the treatment group (novel drug) and the control group (standard therapy).
 
[[Image:ARRequation.jpg|800px]]


Shown below is a detailed explanation of the calculation of NNT:<br>
Shown below is a detailed explanation of the calculation of NNT:<br>
Rate of recurrence of ACS in the drug group: (200/2000)x100= 10%<br>
Rate of ACS recurrence in the drug group: (200/2000) x 100 = 10%<br>
Rate of recurrence of ACS in the placebo group: (540/2400)x100= 22.5%<br>
Rate of ACS recurrence in the placebo group: (540/2400) x 100 = 22.5%<br>
Absolute risk reduction= 22.5%- 10%= 12.5%<br>
Absolute risk reduction (ARR) = 22.5 - 10 = 12.5% = 0.125<br>
NNT= 1/0.125=8<br>
NNT = 1/0.125 = 8 patients
 
Educational objective: The number need to treat (NNT) indicates how many patients would require treatment with a form of [[medication]] to reduce the expected number of cases of a defined endpoint by one. NNT is calculated as the inverse of the relative risk reduction.
|AnswerA=4
|AnswerA=4
|AnswerAExp=This number is incorrect.
|AnswerAExp=This number is incorrect.
|AnswerB=8
|AnswerB=8
|AnswerBExp=In this question the drug reduces the risk of recurrence of [[ACS]] from 22.5% to 10%. Therefore the absolute risk reduction is 12.5%. The NNT for a 5-year treatment with the drug is the inverse of the [[absolute risk reduction]], and it is 8%.
|AnswerBExp=In this vignette, the novel agent reduces the risk of ACS recurrence from 22.5% to 10%. Therefore the absolute risk reduction is 12.5%. The NNT for a 5-year treatment with the novel agent is the inverse of the [[absolute risk reduction]]. NNT = 1/0.125 = 8 patients
|AnswerC=16
|AnswerC=16
|AnswerCExp=This number is incorrect.
|AnswerCExp=This number is incorrect.
Line 40: Line 42:
|AnswerE=64
|AnswerE=64
|AnswerEExp=This number is incorrect.
|AnswerEExp=This number is incorrect.
|EducationalObjectives=The number need to treat (NNT) is defined as the number of patients who require treatment with a form of [[medication]] in order to reduce the expected number of cases of a defined endpoint by one. NNT is calculated as the inverse of the absolute risk reduction. NNT=1/ARR. ARR is the absolute difference in the event rate between the treatment group and the control group.
[[Image:ARRequation.jpg|800px]]
|References=First Aid 2014 page 53
|RightAnswer=B
|RightAnswer=B
|WBRKeyword=Number needed to treat, NNT
|WBRKeyword=Number needed to treat, NNT, Absolute risk reduction, ARR, Endpoint, ACS, Acute coronary syndrome
|Approved=No
|Approved=Yes
|=12.5%<br>
NNT= 1/0.125 = 8 patients<br>
}}
}}

Latest revision as of 01:14, 28 October 2020

 
Author [[PageAuthor::Rim Halaby, M.D. [1] (Reviewed by Rim Halaby, M.D. [2])]]
Exam Type ExamType::USMLE Step 1
Main Category MainCategory::Biostatistics/Epidemiology
Sub Category SubCategory::Cardiology
Prompt [[Prompt::A study addresses the secondary prevention of acute coronary syndrome (ACS) using a novel cholesterol-lowering agent. After 5 years, follow-up of 4400 ACS patients reveals recurrence of at least 1 ACS event among 200 out of 2000 subjects who were administered the novel agent vs. 540 out of 2400 subjects who were administered standard therapy. Through 5 years, how many patients should be administered the novel agent to prevent at least 1 ACS event?]]
Answer A AnswerA::4
Answer A Explanation AnswerAExp::This number is incorrect.
Answer B AnswerB::8
Answer B Explanation [[AnswerBExp::In this vignette, the novel agent reduces the risk of ACS recurrence from 22.5% to 10%. Therefore the absolute risk reduction is 12.5%. The NNT for a 5-year treatment with the novel agent is the inverse of the absolute risk reduction. NNT = 1/0.125 = 8 patients]]
Answer C AnswerC::16
Answer C Explanation AnswerCExp::This number is incorrect.
Answer D AnswerD::32
Answer D Explanation AnswerDExp::This number is incorrect.
Answer E AnswerE::64
Answer E Explanation AnswerEExp::This number is incorrect.
Right Answer RightAnswer::B
Explanation [[Explanation::The number needed to treat (NNT) is an epidemiological measure that indicates how many patients would require treatment with a form of medication to reduce the expected number of cases of a defined endpoint by one. It is defined as the inverse of the absolute risk reduction. In this vignette, the drug reduces the risk of recurrence of ACS from 22.5% to 10%. Therefore the absolute risk reduction is 12.5%. The NNT for a 5-year treatment with the novel cholesterol-lowering agent is the inverse of the absolute risk reduction (ARR), where ARR is the absolute difference in the event rate between the treatment group (novel drug) and the control group (standard therapy).

Shown below is a detailed explanation of the calculation of NNT:
Rate of ACS recurrence in the drug group: (200/2000) x 100 = 10%
Rate of ACS recurrence in the placebo group: (540/2400) x 100 = 22.5%
Absolute risk reduction (ARR) = 22.5 - 10 = 12.5% = 0.125
NNT = 1/0.125 = 8 patients
Educational Objective: The number need to treat (NNT) is defined as the number of patients who require treatment with a form of medication in order to reduce the expected number of cases of a defined endpoint by one. NNT is calculated as the inverse of the absolute risk reduction. NNT=1/ARR. ARR is the absolute difference in the event rate between the treatment group and the control group.


References: First Aid 2014 page 53]]

Approved Approved::Yes
Keyword WBRKeyword::Number needed to treat, WBRKeyword::NNT, WBRKeyword::Absolute risk reduction, WBRKeyword::ARR, WBRKeyword::Endpoint, WBRKeyword::ACS, WBRKeyword::Acute coronary syndrome
Linked Question Linked::
Order in Linked Questions LinkedOrder::